Gerwin Roks
Research Subjects
Research Interests
Gerwin Roks has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Annemarie W Oldenbeuving
2 shared publicationsA. W. Oldenbeuving
Department of neurology, St Elisabeth Hospital, Tilburg, the netherlands
1 shared publication- Annemarie W Oldenbeuving
Department of neurology, St Elisabeth Hospital, Tilburg, the netherlands
1 shared publication B. P. W. Jansen
TweeSteden Hospital, Tilburg, The Netherlands
1 shared publication- Ben Pw Jansen
Department of neurology, TweeSteden Hospital, Tilburg, the netherlands
1 shared publication C J Stam
VU University Medical Center, Department of Clinical Neurophysiology, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- 15 February 2016
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 33 (4) , 339-345
Acute Alcohol Intoxication in Patients with Mild Traumatic Brain Injury: Characteristics, Recovery, and Outcome
A substantial number of patients (30% to 50%) sustains a mild traumatic brain injury (mTBI) while they are under the influence of alcohol. An acute alcohol intoxication (AAI) at the time of injury has been subject of research in severe TBI, but little is known about the relation between AAI and mTBI. This study aimed to describe the characteristics of this intoxicated subgroup and evaluate recovery and outcome in comparison to sober mTBI patients. We included 528 mTBI patients (Glasgow Coma Scale [GCS] score 13–15) admitted to two Level 1 trauma centers as part of a prospective follow-up study. We compared clinical characteristics, demographics, and injury mechanism between groups. Post-concussive complaints, mood disorders, and post-traumatic stress-related complaints were assessed at 2 weeks post-injury, and outcome at 6 months with the Glasgow Outcome Scale Extended (GOSE). Thirty-three percent of the mTBI patients were intoxicated. Results showed that the intoxicated group was younger (36 vs. 40 years; p = 0.001) and were more frequently of male gender (78% vs. 60%; p < .001). The groups also differed in injury related characteristics, with intoxicated patients more frequently sustaining falls or violence-related injuries. The intoxicated group was assessed with a lower GCS score and had a higher hospital admission rate. However, at 2 weeks post-injury, intoxicated patients reported less complaints than the non-alcohol group and showed a better recovery at 6 months (average GOSE scores 7 vs. 7.3; p = 0.030). We conclude that AAI in mTBI represents a characteristically different group, which has implications for prevention measures, as well as the course of recovery.
- 15 February 2016
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 33 (4) , 339-345
Acute Alcohol Intoxication in Patients with Mild Traumatic Brain Injury: Characteristics, Recovery, and Outcome
A substantial number of patients (30% to 50%) sustains a mild traumatic brain injury (mTBI) while they are under the influence of alcohol. An acute alcohol intoxication (AAI) at the time of injury has been subject of research in severe TBI, but little is known about the relation between AAI and mTBI. This study aimed to describe the characteristics of this intoxicated subgroup and evaluate recovery and outcome in comparison to sober mTBI patients. We included 528 mTBI patients (Glasgow Coma Scale [GCS] score 13–15) admitted to two Level 1 trauma centers as part of a prospective follow-up study. We compared clinical characteristics, demographics, and injury mechanism between groups. Post-concussive complaints, mood disorders, and post-traumatic stress-related complaints were assessed at 2 weeks post-injury, and outcome at 6 months with the Glasgow Outcome Scale Extended (GOSE). Thirty-three percent of the mTBI patients were intoxicated. Results showed that the intoxicated group was younger (36 vs. 40 years; p = 0.001) and were more frequently of male gender (78% vs. 60%; p < .001). The groups also differed in injury related characteristics, with intoxicated patients more frequently sustaining falls or violence-related injuries. The intoxicated group was assessed with a lower GCS score and had a higher hospital admission rate. However, at 2 weeks post-injury, intoxicated patients reported less complaints than the non-alcohol group and showed a better recovery at 6 months (average GOSE scores 7 vs. 7.3; p = 0.030). We conclude that AAI in mTBI represents a characteristically different group, which has implications for prevention measures, as well as the course of recovery.
- Open Access
- 9 August 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
Elevated cerebrospinal fluid tau in Wernicke encephalopathy
Wernicke encephalopathy (WE) commonly presents with oculomotor abnormalities, gait ataxia and confusion. WE can mimic rapidly progressive dementia syndromes, such as Creutzfeldt-Jakob disease (CJD). Cerebrospinal fluid (CSF) tau is frequently used for diagnosis of several dementia subtypes, predominantly CJD and Alzheimer's disease. The combination of very high CSF tau (tau) and normal phosphorylated tau (p-tau) levels is almost exclusively seen in aggressive diseases, such as CJD. The authors present a case of a woman with WE, caused by chronic insufficient dietary intake, with highly elevated CSF tau and normal p-tau. The clinical symptoms and CSF findings raised the suspicion of CJD. However, shortly after immediate treatment with thiamine the patient clinically improved. At follow-up, 2.5 months later, she had made a good recovery. This case of rapidly progressive dementia illustrates that, even in the case of a highly elevated CSF tau, clinicians should be alert for treatable causes such as WE.
- 9 August 2012
- Published by BMJ in BMJ Case Reports
- Vol. 2012
Open AccessElevated cerebrospinal fluid tau in Wernicke encephalopathy
Wernicke encephalopathy (WE) commonly presents with oculomotor abnormalities, gait ataxia and confusion. WE can mimic rapidly progressive dementia syndromes, such as Creutzfeldt-Jakob disease (CJD). Cerebrospinal fluid (CSF) tau is frequently used for diagnosis of several dementia subtypes, predominantly CJD and Alzheimer's disease. The combination of very high CSF tau (tau) and normal phosphorylated tau (p-tau) levels is almost exclusively seen in aggressive diseases, such as CJD. The authors present a case of a woman with WE, caused by chronic insufficient dietary intake, with highly elevated CSF tau and normal p-tau. The clinical symptoms and CSF findings raised the suspicion of CJD. However, shortly after immediate treatment with thiamine the patient clinically improved. At follow-up, 2.5 months later, she had made a good recovery. This case of rapidly progressive dementia illustrates that, even in the case of a highly elevated CSF tau, clinicians should be alert for treatable causes such as WE.
- 1 January 2010
- Vol. 154, A1290
[Delirium on intensive care frequently missed: clinical impression alone is not enough].
To compare the sensitivity and specificity of a routine assessment (clinical impression) with a structured assessment which uses a validated assessment scale for the recognition of delirium on the intensive care unit (ICU). Observational study. During their admission to the intensive care unit, 103 patients were assessed daily (with a maximum of 40 days) for the presence of delirium using the Confusion assessment method for the intensive care unit (CAM-ICU). Their physicians indicated whether or not they considered the patient delirious. These findings were compared. For all patients daily information was also collected about fixation and complications, such as self-extubation or self-removal of catheters. The patients were assessed for a period of 502 patient-days. CAM-ICU scores were positive (n = 108), negative (n = 235) or non-assessable because the patient was comatosed or deeply sedated (n = 159). The sensitivity of clinical detection by the physicians was 45% in comparison to the CAM-ICU. The specificity was high (97%). The diagnosis delirium is frequently missed on the ICU when only based on clinical impression. Routine assessment using a validated assessment scale such as the CAM-ICU might possibly improve this.
- 1 January 2010
- Vol. 154, A1290
[Delirium on intensive care frequently missed: clinical impression alone is not enough].
To compare the sensitivity and specificity of a routine assessment (clinical impression) with a structured assessment which uses a validated assessment scale for the recognition of delirium on the intensive care unit (ICU). Observational study. During their admission to the intensive care unit, 103 patients were assessed daily (with a maximum of 40 days) for the presence of delirium using the Confusion assessment method for the intensive care unit (CAM-ICU). Their physicians indicated whether or not they considered the patient delirious. These findings were compared. For all patients daily information was also collected about fixation and complications, such as self-extubation or self-removal of catheters. The patients were assessed for a period of 502 patient-days. CAM-ICU scores were positive (n = 108), negative (n = 235) or non-assessable because the patient was comatosed or deeply sedated (n = 159). The sensitivity of clinical detection by the physicians was 45% in comparison to the CAM-ICU. The specificity was high (97%). The diagnosis delirium is frequently missed on the ICU when only based on clinical impression. Routine assessment using a validated assessment scale such as the CAM-ICU might possibly improve this.
- 1 January 2010
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Neurology
- Vol. 05 (02)
Rivastigmine for the Treatment of Delirium—A Review
Delirium is a common disorder in hospitalized elderly patients. It is a complex neuropsychiatric syndrome with disturbance of consciousness, attention, cognition, and perception. Treatment is based on identification and correction of the underlying cause together with symptomatic treatment. Decreased cholinergic activity is often considered to be one of the essential features in the pathophysiology of delirium. Therefore, correction of this cholinergic deficiency appears to be a promising approach. In this article we describe the pathophysiology of delirium, the pharmacological properties of rivastigmine, and the use of rivastigmine in the prevention and symptomatic treatment of delirium.
- 1 January 2010
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Neurology
- Vol. 05 (02)
Rivastigmine for the Treatment of Delirium—A Review
Delirium is a common disorder in hospitalized elderly patients. It is a complex neuropsychiatric syndrome with disturbance of consciousness, attention, cognition, and perception. Treatment is based on identification and correction of the underlying cause together with symptomatic treatment. Decreased cholinergic activity is often considered to be one of the essential features in the pathophysiology of delirium. Therefore, correction of this cholinergic deficiency appears to be a promising approach. In this article we describe the pathophysiology of delirium, the pharmacological properties of rivastigmine, and the use of rivastigmine in the prevention and symptomatic treatment of delirium.
- Open Access
- 20 September 2008
- Published by Springer Nature in BMC Neurology
- Vol. 8 (1) , 34
A pilot study of rivastigmine in the treatment of delirium after stroke: A safe alternative
Background: Delirium is a common disorder in the early phase of stroke. Given the presumed cholinergic deficiency in delirium, we tested treatment with the acetylcholinesterase inhibitor rivastigmine. Methods: This pilot study was performed within an epidemiological study. In 527 consecutive stroke patients presence of delirium was assessed during the first week with the confusion assessment method. Severity was scored with the delirium rating scale (DRS). Sixty-two patients developed a delirium in the acute phase of stroke. Only patients with a severe and persistent delirium (defined as a DRS of 12 or more for more than 24 hours) were enrolled in the present study. In total 26 fulfilled these criteria of whom 17 were treated with orally administered rivastigmine with a total dose between 3 and 12 mg a day. Eight patients could not be treated because of dysphagia and one because of early discharge. Results: No major side effects were recorded. In 16 patients there was a considerable decrease in severity of delirium. The mean DRS declined from 14.8 on day one to 8.5 after therapy and 5.6 after tapering. The mean duration of delirium was 6.7 days (range; 2–17). Conclusion: Rivastigmine is safe in stroke patients with delirium even after rapid titration. In the majority of patients the delirium improved after treatment. A randomized controlled trial is needed to establish the usefulness of rivastigmine in delirium after stroke. Trial registration: Nederlands Trial Register NTR1395
- 20 September 2008
- Published by Springer Nature in BMC Neurology
- Vol. 8 (1) , 34
Open AccessA pilot study of rivastigmine in the treatment of delirium after stroke: A safe alternative
Background: Delirium is a common disorder in the early phase of stroke. Given the presumed cholinergic deficiency in delirium, we tested treatment with the acetylcholinesterase inhibitor rivastigmine. Methods: This pilot study was performed within an epidemiological study. In 527 consecutive stroke patients presence of delirium was assessed during the first week with the confusion assessment method. Severity was scored with the delirium rating scale (DRS). Sixty-two patients developed a delirium in the acute phase of stroke. Only patients with a severe and persistent delirium (defined as a DRS of 12 or more for more than 24 hours) were enrolled in the present study. In total 26 fulfilled these criteria of whom 17 were treated with orally administered rivastigmine with a total dose between 3 and 12 mg a day. Eight patients could not be treated because of dysphagia and one because of early discharge. Results: No major side effects were recorded. In 16 patients there was a considerable decrease in severity of delirium. The mean DRS declined from 14.8 on day one to 8.5 after therapy and 5.6 after tapering. The mean duration of delirium was 6.7 days (range; 2–17). Conclusion: Rivastigmine is safe in stroke patients with delirium even after rapid titration. In the majority of patients the delirium improved after treatment. A randomized controlled trial is needed to establish the usefulness of rivastigmine in delirium after stroke. Trial registration: Nederlands Trial Register NTR1395
- 1 April 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 79 (4) , 377-380
The use of EEG in the diagnosis of dementia with Lewy bodies
Although reports on EEG in dementia with Lewy bodies (DLB) are conflicting, the recent diagnostic guidelines define EEG abnormalities as being supportive for the diagnosis. We examined EEG abnormalities in 18 patients with DLB, 34 patients with Alzheimer’s disease (AD) and 36 patients with subjective memory complaints (SMC) using the Grand Total EEG (GTE) score. There was a difference in median GTE score of DLB (11.0), AD (4.8) and SMC (2.5) (p<0.001). Patients with DLB had higher scores than patients with AD. ROC analyses revealed that patients with DLB could be distinguished from those with AD with a sensitivity of 72% and a specificity of 85% at a GTE cut-off of 9.5. The association between GTE and DLB was independent of age, gender, Mini Mental State Examination and medication use. Frontal intermittent rhythmic delta activity (FIRDA) was found in 2.9% of the patients with AD and in 33.3% of the patients with DLB. The GTE is a simple EEG scoring method that can be helpful in the differential diagnosis between DLB and AD with good sensitivity and specificity.
- 1 April 2008
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 79 (4) , 377-380
The use of EEG in the diagnosis of dementia with Lewy bodies
Although reports on EEG in dementia with Lewy bodies (DLB) are conflicting, the recent diagnostic guidelines define EEG abnormalities as being supportive for the diagnosis. We examined EEG abnormalities in 18 patients with DLB, 34 patients with Alzheimer’s disease (AD) and 36 patients with subjective memory complaints (SMC) using the Grand Total EEG (GTE) score. There was a difference in median GTE score of DLB (11.0), AD (4.8) and SMC (2.5) (p<0.001). Patients with DLB had higher scores than patients with AD. ROC analyses revealed that patients with DLB could be distinguished from those with AD with a sensitivity of 72% and a specificity of 85% at a GTE cut-off of 9.5. The association between GTE and DLB was independent of age, gender, Mini Mental State Examination and medication use. Frontal intermittent rhythmic delta activity (FIRDA) was found in 2.9% of the patients with AD and in 33.3% of the patients with DLB. The GTE is a simple EEG scoring method that can be helpful in the differential diagnosis between DLB and AD with good sensitivity and specificity.
- 1 November 2007
- Published by SAGE Publications in International Journal of Stroke
- Vol. 2 (4) , 270-275
Delirium in Acute Stroke: A Review
Background: Delirium is a complex neuropsychiatric syndrome characterized by disturbances of consciousness, attention, cognition, and perception. It may be the presenting feature of acute stroke, but more often it complicates the clinical course in the early stage of rehabilitation. Summary of review: Risk factors for delirium are older age, pre-existing cognitive decline, metabolic disturbances, infections, and polypharmacy. Recognition of delirium in patients with stroke is important because of its association with a longer stay in the hospital, a poor functional outcome, and an increased risk of developing dementia. The diagnosis may be difficult because of the fluctuating course and the neurological deficits that are caused by the stroke. Nonpharmacological preventive measures, early identification, and additional medical intervention are the key measures in the management of delirium after stroke. Conclusion: This review describes incidence, risk factors, pathophysiology, diagnostic tools, and management of delirium in patients with a recent stroke.
- 1 November 2007
- Published by SAGE Publications in International Journal of Stroke
- Vol. 2 (4) , 270-275
Delirium in Acute Stroke: A Review
Background: Delirium is a complex neuropsychiatric syndrome characterized by disturbances of consciousness, attention, cognition, and perception. It may be the presenting feature of acute stroke, but more often it complicates the clinical course in the early stage of rehabilitation. Summary of review: Risk factors for delirium are older age, pre-existing cognitive decline, metabolic disturbances, infections, and polypharmacy. Recognition of delirium in patients with stroke is important because of its association with a longer stay in the hospital, a poor functional outcome, and an increased risk of developing dementia. The diagnosis may be difficult because of the fluctuating course and the neurological deficits that are caused by the stroke. Nonpharmacological preventive measures, early identification, and additional medical intervention are the key measures in the management of delirium after stroke. Conclusion: This review describes incidence, risk factors, pathophysiology, diagnostic tools, and management of delirium in patients with a recent stroke.
- 1 February 2003
- Vol. 34 (1) , 13-20
[Alzheimer's disease. Present and future role of genetics].
Research in the field of Alzheimer's disease has shown that genetic factors play an important role in the aetiology of the disease. Until now, four genes have been found to be implicated in Alzheimer's disease. Mutations in the amyloid precursor protein gene (APP) and the presenilin genes (PSEN1 en PSEN2) cause early onset Alzheimer's disease. These mutations segregate in an autosomal dominant pattern. The fourth gene involved in Alzheimer's disease is the apolipoprotein E gene (APOE). Carriers of the E4 variant of APOE have an increased risk of Alzheimer's disease. Being a carrier of this E4 variant increases the risk of both early- and late-onset Alzheimer's disease. Of the four Alzheimer-genes, APOE plays the most important role in the general population. Mutations in APP and the presenilin genes account for less than 1% of the prevalence of the disease in the general population compared to 10-17% for the APOE variation. Up till now the impact of genetics in daily clinical practice is very limited. However, genetics has caused major progress in molecular-biological knowledge, especially of the amyloid metabolism, creating optimism about novel biological markers and eventually therapeutic strategies. In Alzheimer's genetics break-throughs are to be expected using classical methods such as the candidate-gene or linkage approach. Novel strategies such as genetic research in isolated populations are promising.
- 1 February 2003
- Vol. 34 (1) , 13-20
[Alzheimer's disease. Present and future role of genetics].
Research in the field of Alzheimer's disease has shown that genetic factors play an important role in the aetiology of the disease. Until now, four genes have been found to be implicated in Alzheimer's disease. Mutations in the amyloid precursor protein gene (APP) and the presenilin genes (PSEN1 en PSEN2) cause early onset Alzheimer's disease. These mutations segregate in an autosomal dominant pattern. The fourth gene involved in Alzheimer's disease is the apolipoprotein E gene (APOE). Carriers of the E4 variant of APOE have an increased risk of Alzheimer's disease. Being a carrier of this E4 variant increases the risk of both early- and late-onset Alzheimer's disease. Of the four Alzheimer-genes, APOE plays the most important role in the general population. Mutations in APP and the presenilin genes account for less than 1% of the prevalence of the disease in the general population compared to 10-17% for the APOE variation. Up till now the impact of genetics in daily clinical practice is very limited. However, genetics has caused major progress in molecular-biological knowledge, especially of the amyloid metabolism, creating optimism about novel biological markers and eventually therapeutic strategies. In Alzheimer's genetics break-throughs are to be expected using classical methods such as the candidate-gene or linkage approach. Novel strategies such as genetic research in isolated populations are promising.